A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)

A Single Center, Open Label, Multiple-Dose Oral Oseltamivir Suspension Study in End-Stage-Renal Disease (ESRD) Patients on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)

This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD). Participants will receive 6.5 and 6 weeks of the marketed oral oseltamivir suspension dosed according to the HD or CAPD schedule, respectively.

Inclusion Criteria:

• Adults greater than or equal to (>/=) 18 years of age
• ESRD defined as no residual renal function or a creatinine clearance (CrCl) less than (<) 10 milliliters per minute (mL/min)
• Well established HD or CAPD therapy over a period of 3 months with stable CrCl < 10 mL/min
• Body mass index (BMI) 18 to 34 kilograms per meter-squared (kg/m^2)
• Use of contraception among women of childbearing potential

Exclusion Criteria:

• Clinical significant comorbid disease or terminal illness
• Known human immunodeficiency virus (HIV) or hepatitis B or C
• History of drug or alcohol abuse within the prior year
• Donation or loss of >/= 400 milliliters (mL) of blood in the 3 months prior to Screening
• Participation in a clinical study with an investigational drug in the 3 months prior to study drug
• Pregnant or lactating women